Michael DesJardin
Chief Tech/Sci/R&D Officer at HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Profile
Currently, Michael A. DesJardin occupies the position of Executive VP-Technical Operations & Quality at Horizon Therapeutics Plc and Senior Vice President-Technical Operations at Horizon Pharmaceutical LLC (a subsidiary of Horizon Therapeutics Plc). He is also Senior Vice President-Technical Operations at Horizon Pharmaceutical LLC. He previously held the position of Senior Vice President-Product Development at Jazz Pharmaceuticals Plc and Executive Director-Implant Research & Development at ALZA Corp. Mr. DesJardin received an undergraduate degree from the University of California, Berkeley.
Michael DesJardin active positions
| Companies | Position | Start |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 2017-01-31 |
Former positions of Michael DesJardin
| Companies | Position | End |
|---|---|---|
| RAPTOR PHARMACEUTICAL CORP | Chief Tech/Sci/R&D Officer | 2016-09-30 |
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 2015-02-28 |
| ALZA CORPORATION | Chief Tech/Sci/R&D Officer | - |
Training of Michael DesJardin
| University of California, Berkeley | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| Private companies | 3 |
|---|---|
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
- Stock Market
- Insiders
- Michael DesJardin
